SCHEMBL4515609

SCHEMBL4515609

CCOC(=O)c1cc2c(=O)[nH]c(Cc3cccc(Cl)c3)nc2s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.76
PDE3B Q13370 1/20 0.53
PDE3A Q14432 1/20 0.53
ALOX5 P09917 4/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
PIP4K2A P48426 1/20 0.46
PTGES O14684 1/20 0.46
CCNE2 O96020 1/20 0.45
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
KCNH2 Q12809 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
PDE9A O76083 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491252 0.89 PDE5A (0.61) PDE5APDE3BPDE3AKMT2AMEN1
SCHEMBL4522382 0.87 PDE5A (0.57) PDE5AALOX5KMT2AMEN1SMN1; SMN2
SCHEMBL3492301 0.86 PDE5A (1.00) PDE5AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL38743 0.85 PDE5A (0.82) PDE5APDE3BPDE3AKMT2ASMN1; SMN2
SCHEMBL4520486 0.85 PDE5A (0.56) PDE5AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL4518642 0.84 PIP4K2A (0.66) PDE5APDE3BPDE3AKMT2AMEN1
SCHEMBL46289 0.84 PDE5A (0.76) PDE5APDE3BPDE3AALOX5KMT2A
SCHEMBL4511837 0.82 PDE5A (0.50) PDE5AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL4530199 0.81 SMN1; SMN2 (0.50) PDE5AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL16175587 0.81 PDE5A (0.74) PDE5APDE3BPDE3AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 PDE5A 25/4885PDE3B 46/4885PDE3A 31/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 PDE5A 25/4885PDE3B 46/4885PDE3A 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.